Remedy Plan Therapeutics
James received his B.S. in Biology from the University of Maryland, College Park, with a focus on evolutionary development and molecular biology. His past research includes risk assessment for using dsRNA in agricultural settings as a species-specific pesticide through RNA interference. At Remedy Plan, James supports mechanisms of action and target engagement studies.
This person is not in any offices
Remedy Plan Therapeutics
Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.